Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

Go back to Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
(NYSE: RCUS) Delayed: 24.41 +0.58 (2.43%)
Previous Close $23.83    52 Week High $ 
Open $23.89    52 Week Low $ 
Day High $24.58    P/E N/A 
Day Low $23.75    EPS $ 
Volume 795,188       

Stratcomm Media, Ltd. (NASDAQ: SMMT) Delayed: 17.59 +0.42 (2.45%)
Previous Close $17.17    52 Week High $19.75 
Open $17.36    52 Week Low $4.26 
Day High $17.62    P/E N/A 
Day Low $16.82    EPS $0.00 
Volume 5,754,954